CogState Osake

CogState Rule of 40

Delisted·15.6.2026

40. säännön sääntö yhtiöstä CogState (CGS.AX) 5.8.2026 päivämäärällä on 46,88 %. Edellisenä vuonna 40. säännön sääntö oli 23,65 % — muutos 98,22 % (korkeampi).

Rule of 40

46,88 %

YoY

98,22%

Viimeksi päivitetty:

40. säännön sääntö yhtiöstä CogState on 2026 46,88 % . 40. säännön sääntö yhtiöstä CogState oli 2025 23,65 % . Se laskee 98,22% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

CogState Osakeanalyysi

Mitä CogState tekee? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset CogState osakkeesta

Yhtiön CogState 40. säännön sääntö on 46,88 % vuonna 2026.

Eurpoolissa voit löytää 40. säännön sääntö CogState:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

40. säännön sääntö sanoo, että yrityksen tulojen kasvuvauhti plus voittomarginaali olisi ylitettävä 40 %. Sitä käytetään laajalti SaaS- ja nopeasti kasvavien yritysten arvioimiseen.

Access this data via the Eulerpool API

Laatu — CogState

Kaikki tunnusluvut — CogState